The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Relationship between Antiphospholipid Antibodies and Major Adverse Cardiovascular Events after Drug-Eluting Stent Implantation in Patients with Acute Myocardial Infarction

약물방출 스텐트 시술을 받은 급성 심근경색증 환자에서 항인지질항체의 존재가 주요 심혈관 사건에 미치는 영향

  • Jung, Yeoun-Su (Department of Internal Medicine, Daegu Fatima Hospital) ;
  • Lee, Bong-Ryeol (Department of Internal Medicine, Daegu Fatima Hospital) ;
  • Ryu, Han-Jun (Department of Internal Medicine, Daegu Fatima Hospital) ;
  • Park, Min-Kyu (Department of Internal Medicine, Daegu Fatima Hospital) ;
  • Kim, Min-Hee (Department of Internal Medicine, Daegu Fatima Hospital) ;
  • Jung, Ho-Jin (Department of Internal Medicine, Daegu Fatima Hospital) ;
  • Lee, Jun-Young (Department of Internal Medicine, Daegu Fatima Hospital) ;
  • Kang, Hyun-Jae (Department of Internal Medicine, Daegu Fatima Hospital) ;
  • Jung, Byung-Chun (Department of Internal Medicine, Daegu Fatima Hospital) ;
  • Chang, Soon-Hee (Department of labarotory Medicine, Daegu Fatima Hospital)
  • Received : 2012.07.14
  • Accepted : 2012.10.29
  • Published : 2013.05.01
⟨ Previous Next ⟩

Abstract

Background/Aims: Several studies have reported an association between antiphospholipid antibodies (APA) and major adverse cardiovascular events (MACE) following acute myocardial infarction (AMI). However, the relationship between APA and the prognosis after drug-eluting stent (DES) implantation in patients with AMI is not known. Methods: Thus, we investigated the relationship between the incidence of MACE and APA levels in patients with AMI who underwent successful DES implantation. Results: Of 182 patients, 78 (42.9%) tested positive for APA. Lupus anticoagulant was positive in 37.6% (68 of 181) patients, anticardiolipin antibody IgM was positive in 8.3% (15 of 180), and anticardiolipin antibody IgG was positive in 1.7% (3 of 180) patients. At follow up, a MACE had occurred in 11 (14.1%) patients in the APA-positive group and in seven (6.7%) patients in the APA-negative group (p = 0.099). Conclusions: No significant association was found between the incidence of MACE and the presence of APA in patients with AMI who underwent successful DES implantation.

목적: 항인지질항체는 급성 심근경색증의 발병과 연관이 있는 것으로 알려져 있다. 하지만 약물방출 스텐트를 삽입한 급성 심근경색증 환자에게서 항인지질항체와 주요 심혈관 사건의 발생과의 연관성은 잘 알려져 있지 않다. 이 연구의 목적은 약물방출 스텐트를 시술한 급성 심근경색증 환자에서 항인지질항체와 주요 심혈관 사건 발생과의 연관성을 알아보는 것이다. 방법: 본 연구는 성공적으로 약물방출 스텐트를 삽입한 급성 심근경색증 생존자를 대상으로 항인지질항체 양성군과 음성군으로 나누어 주요 심혈관 사건과의 연관성에 대해 후향적으로 연구하였다. 결과: 항인지질항체 양성군에서 더 고령이었으며, 뇌졸중의 과거력이 더 많았고, 급성 심근경색증으로 내원 당시 Killip class는 더 높았다. 관상동맥 조영술상에서 다혈관 질환의 빈도가 양성군에서 더 잦았다. 그러나 주요 심혈관 사건에 있어 항인지질항체 양성군과 음성군 사이에 통계적인 차이가 없었다(p = 0.099). 결론: 항인지질항체의 존재는 급성 심근경색증으로 약물방출 스텐트를 삽입한 환자에게서 주요 심혈관 사건과 의미있는 연관성이 없었다.

Keywords

References

  1. Brar SS, Leon MB, Stone GW, et al. Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis. J Am Coll Cardiol 2009;53:1677-1689. https://doi.org/10.1016/j.jacc.2009.03.013
  2. Kalesan B, Pilgrim T, Heinimann K, et al. Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012;33:977-987. https://doi.org/10.1093/eurheartj/ehs036
  3. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-2130. https://doi.org/10.1001/jama.293.17.2126
  4. Acar G, Dogan A, Altinbas A, Turker Y. Recurrent acute stent thrombosis associated with protein C and S deficiencies. Int J Cardiovasc Imaging 2006;22:333-337. https://doi.org/10.1007/s10554-005-9074-3
  5. Turgut T, Harjai KJ, Edupuganti R, et al. Acute coronary occlusion and in-stent thrombosis in a patient with essential thrombocythemia. Cathet Cardiovasc Diagn 1998;45: 428-433. https://doi.org/10.1002/(SICI)1097-0304(199812)45:4<428::AID-CCD19>3.0.CO;2-E
  6. Vaarala O, Manttari M, Manninen V, et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995;91:23-27. https://doi.org/10.1161/01.CIR.91.1.23
  7. Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol 2009;8:998-1005. https://doi.org/10.1016/S1474-4422(09)70239-X
  8. Sletnes KE, Smith P, Abdelnoor M, Arnesen H, Wisløff F. Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke. Lancet 1992;339:451-453. https://doi.org/10.1016/0140-6736(92)91057-F
  9. Greco TP, Conti-Kelly AM, Greco T Jr, et al. Newer antiphospholipid antibodies predict adverse outcomes in patients with acute coronary syndrome. Am J Clin Pathol 2009;132:613-620. https://doi.org/10.1309/AJCP2FJUT2YZGITK
  10. Killip T 3rd, Kimball JT. Treatment of myocardial infarction in a coronary care unit: a two year experience with 250 patients. Am J Cardiol 1967;20:457-464. https://doi.org/10.1016/0002-9149(67)90023-9
  11. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-2351. https://doi.org/10.1161/CIRCULATIONAHA.106.685313
  12. Long BR, Leya F. The role of antiphospholipid syndrome in cardiovascular disease. Hematol Oncol Clin North Am 2008;22:79-94. https://doi.org/10.1016/j.hoc.2007.10.002
  13. Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 2000;15:145-151. https://doi.org/10.1006/jaut.2000.0409
  14. Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb Res 2004;114:593-595. https://doi.org/10.1016/j.thromres.2004.07.012
  15. Vaarala O, Mänttäri M, Manninen V, et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995;91:23-27. https://doi.org/10.1161/01.CIR.91.1.23
  16. Bili A, Moss AJ, Francis CW, et al. Anticardiolipin antibodies and recurrent coronary events: a prospective study of 1150 patients: Thrombogenic Factors, and Recurrent Coronary Events Investigators. Circulation 2000;102:1258-1263. https://doi.org/10.1161/01.CIR.102.11.1258
  17. Su HM, Lee KT, Chu CS, Sheu SH, Lai WT. Acute thrombosis after elective direct intracoronary stenting in primary antiphospholipid syndrome: a case report. Kaohsiung J Med Sci 2003;19:177-182. https://doi.org/10.1016/S1607-551X(09)70468-1
  18. Weissman A, Coplan NL. Antiphospholipid antibody syndrome and acute stent thrombosis. Rev Cardiovasc Med 2006;7:244-246.
  19. Niessner A, Hornykewycz S, Graf S, et al. Pre-existing anticardiolipin antibodies and development of restenosis after coronary balloon angioplasty: predictive value for a complicated course? Blood Coagul Fibrinolysis 2004;15: 311-316. https://doi.org/10.1097/00001721-200406000-00004
  20. Gürlek A, Ozdöl C, Pamir G, Dinçer I, Tutkak H, Oral D. Association between anticardiolipin antibodies and recurrent cardiac events in patients with acute coronary syndrome. Int Heart J 2005;46:631-638. https://doi.org/10.1536/ihj.46.631
  21. Sharma S, Malhotra A, Sharma YP, et al. Association of anticardiolipin antibodies levels with instent restenosis in patients with coronary artery disease. Indian J Physiol Pharmacol 2008;52:288-292.
  22. Chiarugi L, Prisco D, Antonucci E, et al. Lipoprotein (a) and anticardiolipin antibodies are risk factors for clinically relevant restenosis after elective balloon percutaneous transluminal coronary angioplasty. Atherosclerosis 2001; 154:129-135. https://doi.org/10.1016/S0021-9150(00)00439-1
  23. Eber B, Kronberger-Schaffer E, Brussee H, et al. Anticardiolipin antibodies are no marker for survived myocardial infarction. Klin Wochenschr 1990;68:594-596. https://doi.org/10.1007/BF01660956
  24. Vuilleumier N, Pagano S, Lahlou K, et al. Head-to-head comparison of auto-antibodies for cardiovascular outcome prediction after myocardial infarction: a prospective study. J Clinic Experiment Cardiol 2011;2:169. doi:10.4172/2155- 9880.1000169
  25. Zuckerman E, Toubi E, Shiran A, et al. Anticardiolipin antibodies and acute myocardial infarction in non-systemic lupus erythmatosus patients: a controlled prospective study. Am J Med 1996;104:381-386.
  26. Vianna JL, Khamashta MA, Ordi-Ros J, et al. Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients. Am J Med 1994;96:3-9. https://doi.org/10.1016/0002-9343(94)90108-2

Cited by

  1. 심장 혈관계 시스템의 교육 모형 고안 vol.8, pp.3, 2014, https://doi.org/10.7742/jksr.2014.8.3.117